Published • loading... • Updated
RefleXion Submits FDA 510(k) for Anchor Point Tracking, Advancing the Next Generation of SCINTIX Autonomous Radiotherapy
Summary by HealthTech HotSpot
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
RefleXion Submits FDA 510(k) for Anchor Point Tracking, Advancing the Next Generation of SCINTIX Autonomous Radiotherapy
Submission builds on the X2 platform’s 20X increase in PET sensitivity to further enhance biologic guidance and expand versatility of SCINTIX therapyHAYWARD, Calif.--(BUSINESS WIRE)--#SCINTIX--RefleXion Medical, an external beam theranostic oncology company, today announced it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking clearance for Anchor Point™ Tracking, a next-generation more... The post…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
